Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT03459469 |
| Title | Phase I, Open-label, Non-randomized Study to Evaluate Safety of BC2059 |
| Recruitment | Completed |
| Gender | both |
| Phase | Phase I |
| Variant Requirements | No |
| Sponsors | Iterion Therapeutics |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | USA | CAN |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | United States | Details | |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02215 | United States | Details | |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | United States | Details | |
| The Ohio State University Comprehensive Cancer Center | Columbus | Ohio | 43202 | United States | Details | |
| MD Anderson Cancer Center | Houston | Texas | 770030 | United States | Details | |
| Seattle Cancer Care Alliance | Seattle | Washington | 98109 | United States | Details | |
| Princess Margaret Cancer Center | Toronto | Ontario | Canada | Details |